These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 21468005)

  • 41. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
    Tyagi RK; Mangal S; Garg N; Sharma PK
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. mRNA-based dendritic cell vaccines.
    Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
    Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic cell fusion vaccines for cancer immunotherapy.
    Rosenblatt J; Kufe D; Avigan D
    Expert Opin Biol Ther; 2005 May; 5(5):703-15. PubMed ID: 15934845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
    Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
    Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Dendritic cells for cancer immunotherapy].
    Kakimi K; Kondo A; Matsushita H
    Nihon Rinsho; 2012 Dec; 70(12):2130-5. PubMed ID: 23259385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dendritic cells as natural adjuvants and modulators of immune response in cancer immunotherapy.
    Alli RS; Khar A
    Indian J Biochem Biophys; 2002 Dec; 39(6):363-7. PubMed ID: 22905392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
    Fu C; Zhou L; Mi QS; Jiang A
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RNA-Based Vaccines in Cancer Immunotherapy.
    McNamara MA; Nair SK; Holl EK
    J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.
    Tyagi RK; Parmar R; Patel N
    Hum Vaccin Immunother; 2017 Apr; 13(4):854-866. PubMed ID: 27901642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engineering dendritic cell vaccines to improve cancer immunotherapy.
    Perez CR; De Palma M
    Nat Commun; 2019 Nov; 10(1):5408. PubMed ID: 31776331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.